Andy Extance charts how research into revolutionary targeted protein degradation therapies is moving from serendipity to ...

Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on KYMR stock, giving a Buy rating yesterday.Stay Ahead of the ...

Researchers at EPFL have opened up a world of possibilities in the computational design of molecular interactions for ...

EPFL scientists have used deep learning to design new proteins that bind to complexes involving other small molecules like ...

Girolline, a compound extracted from the sea sponge Pseudaxinyssa cantharella, has been investigated for possible antitumor ...

In a study published today in the Journal of Clinical Investigation, Fred Hutch Cancer Center cancer chemical biologist ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...

Proliferating animal cells maintain a stable size distribution over generations despite fluctuations in cell growth and division size. Previously, we showed that cell size control involves both cell ...

In a report released today, Srikripa Devarakonda from Truist Financial assigned a Buy rating to Kymera Therapeutics (KYMR – Research Report).

Cambridge, UK, 13 January 2025 – Amphista Therapeutics, a leader in the discovery of next-generation, Targeted, Protein ...